Search Bar & Filters
Found 48 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatments for neovascular age-related macular degeneration NVAMD, a condition that affects the eye and vision. This trial aims to compare a new medicine called tiespectus also known as MK-8748 or EYE201 with the standard treatment aflibercept to see if tiespectus works as well for people with NVAMD. The study is a randomized, double-masked, pivotal phase 23 trial focusing on treatment effectiveness and safety. Participants will be assigned to one of three groups one receiving a low dose of tiespectus, another receiving a high dose of tiespectus, and a third group receiving aflibercept. In the tiespectus groups, participants will get three initial injections every four weeks, followed by injections every eight weeks until week 48. After week 48, treatment intervals will be personalized based on individual responses, continuing up to week 92. The aflibercept group also receives three initial injections followed by injections every eight weeks until week 92. Throughout the study, participants will have their vision assessed using a standard eye chart to measure changes in best-corrected visual acuity BCVA from the start through one year. Additional measures include eye imaging to assess retinal thickness and monitoring for any side effects or adverse events up to approximately 96 weeks. The trial will last until June 2028, with ongoing monitoring and follow-up visits to evaluate the safety and effectiveness of the treatments.
Actively Recruiting
Researchers are evaluating the efficacy and safety of EscharEx EX-03 5% formulation compared to a placebo in the treatment of Venous Leg Ulcers VLU. This study involves adults with VLU wounds between 2 cm and 25 cm in size, with wound duration from 4 weeks to 12 months. It aims to assess how well EscharEx helps with debridement and wound bed preparation. Participants will be randomly assigned to receive either EscharEx, a sterile powder containing proteolytic enzymes enriched in bromelain, or a placebo gel without the active enzyme. The powder is mixed with sterile water to form a gel that is applied to the wound area. The study includes several periods a screening period with two visits, a daily treatment period of up to eight daily applications over two weeks, followed by weekly wound management visits for up to 12 weeks, and an optional wound closure confirmation period of up to two weeks. After wound closure, participants enter a 12-week monthly visit period to monitor wound closure durability. During the study, participants undergo clinical assessments of wound debridement and closure, including visual evaluations after each application and over the follow-up periods. Researchers will measure the incidence of complete debridement, time to wound closure, and healthy tissue development. Safety and wound healing progress are monitored throughout. The total participation can last up to 29 weeks, with regular visits to ensure detailed monitoring of wound status and treatment effects.
Actively Recruiting
Researchers are evaluating the effects of three different doses of AZD8965 compared to a placebo in adults aged 40 and older with Idiopathic Pulmonary Fibrosis IPF. This Phase IIb study aims to assess how well AZD8965 works, its safety, and how well participants tolerate it. Participants include those on stable doses of approved antifibrotic therapies and those not receiving such treatments. Participants will be randomly assigned to one of four groups placebo, low dose, medium dose, or high dose of AZD8965. The study lasts 24 weeks and is conducted globally at approximately 200 sites. This is a double-blind, placebo-controlled, parallel-group study, meaning neither participants nor researchers know which treatment any participant receives during the trial. During the study, participants will have their lung function measured by changes in forced vital capacity FVC at 24 weeks, along with monitoring for safety through the recording of adverse events. Additional assessments include examining the relationship between dose and efficacy, rate of lung function decline, and pharmacokinetics of AZD8965. The total participation time is 24 weeks with safety follow-up up to 25 weeks.
Actively Recruiting
This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.
Actively Recruiting
This research aims to evaluate the clinical effectiveness, safety, and tolerability of XEN1101 when used alongside other antiseizure medications in adults with focal-onset seizures. It is a Phase 3, randomized, double-blind, placebo-controlled study involving approximately 360 participants. The study focuses on how XEN1101 affects seizure frequency compared to placebo while monitoring any side effects or safety concerns. Participants will be randomly assigned to one of three groups XEN1101 25 mg, XEN1101 15 mg, or placebo, taken once daily with an evening meal. The study includes a baseline period of up to 9.5 weeks to record seizure frequency, followed by 12 weeks of blinded treatment. After this, those who complete the treatment phase may join an open-label extension study for continued XEN1101 treatment, while others will enter an 8-week post-treatment follow-up period. During the study, participants will keep accurate seizure diaries and attend regular visits for assessments including seizure monitoring, safety checks, and tolerability evaluations. Researchers will measure the median percent change in focal seizure frequency from baseline through the 12-week treatment, along with other outcomes such as the proportion of participants experiencing significant seizure reduction and patient-reported global impressions. Safety is monitored from screening through 56 days after the final dose to ensure participant well-being throughout the trial.
Actively Recruiting
Researchers are evaluating whether baricitinib can delay the onset of clinical type 1 diabetes T1D in children and adults who are at high risk of developing this condition. This Phase 3, double-blind, randomized, placebo-controlled study includes participants aged 1 to less than 36 years with early-stage type 1 diabetes or specific diabetes-related autoantibodies. The study is sponsored by Eli Lilly and Company and aims to understand if baricitinib can postpone progression to stage 3 T1D. Participants will be randomly assigned to receive either baricitinib or a placebo orally. The intervention period may last up to approximately 5 years, during which the time from baseline to diagnosis of stage 3 type 1 diabetes will be closely monitored. Both groups will be followed to assess changes in glucose metabolism, C-peptide levels, body measurements, and quality of life. During the study, participants will undergo regular assessments including blood tests to measure glucose-stimulated C-peptide, glucose levels, and other metabolic markers at baseline and after one year. Additional evaluations include body height, body mass index percentile, and health surveys. Pharmacokinetics of baricitinib will also be monitored up to week 24. Safety and efficacy data will be collected throughout the study period, lasting up to approximately 5 years per participant.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating minimally invasive tests to diagnose pancreatic cancer early and monitor treatment response. This observational study focuses on pancreatic ductal adenocarcinoma and related pancreatic diseases, aiming to improve early detection and surveillance using blood-based biomarkers. The research is sponsored by Memorial Sloan Kettering Cancer Center and includes various patient groups with pancreatic cancer, benign pancreatic conditions, and healthy controls. Participants are divided into cohorts based on their diagnosis, including advanced pancreatic cancer, operable pancreatic cancer, acute and chronic benign pancreatic conditions, pancreatic cysts, and healthy individuals. Blood and sweat samples will be collected, and optional biopsies of tumor or cyst tissue may be performed. Sample collection occurs at enrollment and periodically every 6 to 12 months according to institutional guidelines, with some cohorts closed to new participants. During the study, participants will provide blood samples and possibly tissue samples if clinically safe. Researchers will analyze changes in biomarkers to assess the tests ability to detect early pancreatic cancer over four years. Monitoring includes collecting clinical information and samples at regular intervals. Participation involves ongoing assessments and sample collection to support biomarker development and validation.
Actively Recruiting
Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.
Actively Recruiting
Researchers are evaluating the efficacy and safety of eloralintide compared with placebo in adults with persistent obesity or overweight. Participants may have type 2 diabetes or not, and all are on stable background therapy with a weekly incretin. This phase 3 randomized, double-blind study aims to understand the effects of eloralintide on body weight and related health outcomes. Participants will be randomly assigned to receive one of four doses of eloralintide or a placebo, all given by subcutaneous injection once weekly. The study treatment period lasts for 64 weeks, during which participants receive their assigned injections. This is a parallel group study, meaning each participant receives only one assigned treatment throughout the trial. Participant involvement spans about 80 weeks, including screening, treatment, and follow-up. Researchers will monitor changes in body weight, waist circumference, blood pressure, blood sugar, insulin, kidney function, inflammation markers, and quality of life using questionnaires. Safety and medication use will also be tracked. Visits and assessments will occur regularly to evaluate the treatment effects and participant well-being.
Actively Recruiting
Researchers are evaluating the clinical and endoscopic effects of guselkumab in children aged 2 to 17 with moderately to severely active Crohns Disease who responded to the treatment by Week 12. The study aims to assess the benefits of guselkumab after one year of maintenance therapy. This is a Phase 3 trial sponsored by Janssen Research & Development, LLC. Participants initially receive guselkumab either intravenously or subcutaneously according to their body weight during a 12-week open-label induction phase. Those who respond by Week 12 are then randomly assigned to one of two guselkumab subcutaneous dosing regimens for a double-blind maintenance phase lasting up to Week 48. Participants who do not respond by Week 12 enter an open-label maintenance phase receiving guselkumab subcutaneously up to Week 48. Throughout the study, participants undergo clinical evaluations, endoscopic assessments, and measurement of guselkumab levels at regular intervals up to Week 52. Researchers monitor changes in clinical remission, endoscopic response, growth parameters such as height and weight, and record any adverse events up to Week 64. The total participation duration extends to approximately one year, with ongoing safety and efficacy assessments.
1-10 of 48
1